Abstract
Background Recent data suggest higher COVID-19 rates and severity in Black, Asian, and minority ethnic (BAME) communities. We aimed to study the association between ethnicity and risk of COVID-19 and adjust it by deprivation and previous comorbidity.
Methods Prospective cohort. UK Biobank participants from England linked to Hospital Episode Statistics (HES) and COVID-19 tests until 14 April 2020. COVID-19 infection was based on a positive PCR test. Ethnicity was self-reported and classified using Office of National Statistics groups. Socioeconomic status was based on index of multiple deprivation quintiles. Comorbidities were extracted from HES. We used Poisson regression to estimate rate ratios of infection according to ethnicity, adjusted for socioeconomic status, alcohol drinking, smoking, BMI, age, sex, and comorbidity.
Results 415,582 participants were included, with 2,886 tested and 1,039 positive for COVID-19. The incidence of COVID-19 was 0.85% (0.67% - 1.09%) in Black/Black British participants, 0.47% (0.30%-0.74%) in ‘other’ ethnicities, 0.58% (0.44%-0.76%) in Asian/Asian British, 0.30% (0.11%-0.80%) in Chinese, 0.23% (0.11%-0.52%) in mixed, and 0.23% (0.21%-0.34%) in White. Compared with White participants, Black/Black British participants had an adjusted relative risk (RR) of 2.66 (2.03-3.88), Asian/Asian British participants 2.09 (1.53-2.84), Chinese participants 1.72 (0.64-4.61), ‘other’ ethnicities 1.67 (1.04-2.68), and mixed ethnicities 0.93 (0.41-2.07). Socioeconomic status (adjusted RR 1.73 (1.43-2.1) for the most deprived), was also associated with increased risk of COVID-19.
Conclusion COVID-19 rates in England are higher in BAME communities, and in those living in deprived areas. Public health strategies are needed to reduce COVID-19 infections among the most susceptible groups.
Key Messages
In a cohort of over 480,000 participants from UK Biobank, BAME people are at a 2 to 4-fold higher risk of COVID-19 infection, independent of socioeconomic status, lifestyle, obesity, and comorbidity.
Socioeconomic deprivation, obesity, and certain comorbidities (hypertension, diabetes, heart disease, and renal failure) are also independently associated with increased risk of COVID-19 infection.
Public health strategies to control COVID-19 transmission must take these increased risks into account to protect the most vulnerable people in the UK and worldwide.
Competing Interest Statement
Dr Prieto-Alhambra reports grants and other from AMGEN; grants, non-financial support and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA's department and open for external participants. Mr Prats-Uribe reports grants from Fundación Alfonso Martin Escudero and the Medical Research Council. No other relationships or activities that could appear to have influenced the submitted work. Dr Paredes has received grant support and has participated in advisory meetings from Gilead Sciences, Merck-Sharpe & Dohme and ViiV Healthcare, always for topics not related with the current work.
Funding Statement
The research was partially supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). DPA is funded through an NIHR Senior Research Fellowship (Grant number SRF-2018-11-ST2-004). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health. APU is supported by Fundación Alfonso Martin Escudero and the Medical Research Council (grant numbers MR/K501256/1, MR/N013468/1)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data can be accessed by application to UK Biobank (www.ukbiobank.ac.uk/register-apply). UK Biobank was established as a resource to allow scientists to carry out research into a wide range of diseases. The resource is available for researchers to use without preferential or exclusive access and all researchers, academic and commercial, are subject to the same application criteria, approval procedures and follow-up process.
